Drug Search Results
More Filters [+]

Diquafosol

Alternative Names: diquafosol, ins365, tjo-083, tjo083
Latest Update: 2024-08-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: P2Y Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Ocular,Topical,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Indonesia | Korea | Malaysia | Philippines | Taiwan | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diquafosol

Countries in Clinic: Indonesia, Japan, Korea

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca

Phase 2: Cataract

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TJO-083-A03

P3

Recruiting

Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca

2024-12-31

38%

NCT06146881

P2

Recruiting

Keratoconjunctivitis Sicca|Cataract|Dry Eye Syndromes|Dry Eye Disease

2023-12-15

JapicCTI-205466

P3

Active

Keratoconjunctivitis Sicca

2021-03-31

Recent News Events